CYP3A4/5 (F386) polyclonal Antibody | BS2197

CYP3A4/5 (F386) polyclonal Antibody | BS2197 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC IF

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Background: Cytochrome P450 3A (CYP3A) genes encode monooxygenases—enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A, the most abundant p450 enzyme in human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A family members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster maps to gene locus 7q21.3-q22.1 and consists of four genes (CYP3A4, CYP3A5, CYP3A7 andCYP3A43) and two pseudogenes (CYP3A5P1 and CYP3A5P2) . CYP3A4 is abundant in the endoplasmic reticulum of liver cells and upper intestinal enterocytes. CYP3A4 expression is inducible by glucocorticoids pharmacological agents.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: CYP3A4/5 (F386) polyclonal Antibody detects endogenous levels of CYP3A4/5 protein.

Molecular Weight: ~ 57 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Cytochrome P450 3A4; 1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase; Albendazole sulfoxidase; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Taurochenodeoxycholate 6-alpha-hydroxylase; CYP3A4; CYP3A3; Cytochrome P450 3A5; CYPIIIA5; Cytochrome P450 HLp2; Cytochrome P450-PCN3; CYP3A5

Immunogen: Synthetic peptide, corresponding to amino acids 351-400 of Human CYP3A4.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: